New clinical research is sharpening understanding of bronchopulmonary dysplasia (BPD) risk in preterm infants by connecting hypoxic burden—periods of reduced oxygen—with later BPD development. The retrospective cohort work described in the report highlights how fluctuations rather than single oxygen measures may better predict disease trajectory. Separately, a separate pediatric research report points to dimethyl fumarate’s potential to mitigate BPD, reinforcing a parallel line of investigation into both risk stratification and therapeutics for this high-burden neonatal condition.